Amgen Launches Two Phase 3 Trials for Obesity Drug MariTide
I'm PortAI, I can summarize articles.
Amgen has launched two phase 3 trials for its obesity drug MariTide, as announced by Jay Bradner, Head of Research and Development. One trial targets individuals with obesity or overweight without type 2 diabetes, aiming to enroll 3,500 participants. The second trial focuses on those with obesity or overweight and type 2 diabetes, with a target enrollment of 999 patients. The studies will evaluate various dose levels, with the primary endpoint being the change in baseline body weight at 72 weeks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments